Ipamorelin + Thymosin Alpha-1 Stack: When to Pick One Over the Stack

Why People Pair Them

Neither peptide is FDA-approved, so neither is an approved starting point for a combination [1][2]. The human data discussed below come from separate studies of each peptide.

The usual argument for stacking is mechanistic: ipamorelin stimulates growth hormone release through the ghrelin/growth-hormone-secretagogue receptor rather than the GHRH receptor [8][1], and thymosin alpha-1 is described as an immune modulator that augments T-cell function [9]. Two different targets is a rationale for a study, not a finding.

What Ipamorelin's Own Record Shows

Ipamorelin is a five-amino-acid synthetic peptide identified in 1998. It was developed as an investigational drug for postoperative ileus, and that development was reportedly discontinued after disappointing phase 2 results [8][1].

The one published controlled trial enrolled 117 adults having small or large bowel resection, of whom 114 were analyzed. Patients received 0.03 mg/kg intravenously twice daily or placebo from postoperative day 1 to day 7 or discharge. Median time to first tolerated solid meal was 25.3 hours with ipamorelin and 32.6 hours with placebo, which was not significant (p=0.15), and secondary recovery endpoints did not differ [3].

Adverse events were common in both arms: 87.5% with ipamorelin versus 94.8% with placebo [3]. FDA's own summary of the trial notes low potassium in 12.5% versus 3.4%, insomnia in 10.7% versus 5.2%, high blood sugar at discharge in 14.3% versus 8.6%, and serious adverse events in 17.9% versus 15.5%. Two ipamorelin-treated patients died of surgical complications, and FDA said it is unclear whether the deaths were related to the drug [1][3].

Human dosing has been intravenous only. The volunteer pharmacokinetic study used 15-minute infusions of 4.21 to 140.45 nmol/kg and found a terminal half-life of about 2 hours with a single GH peak at roughly 0.67 hours [10]. FDA found no human pharmacokinetic, safety or efficacy data for subcutaneous ipamorelin, and no approved dose exists [1].

Because ipamorelin stimulates the GH and IGF-1 axis, FDA expects it may carry the risks listed on approved growth hormone labels, including neoplasm, glucose intolerance and diabetes, intracranial hypertension, fluid retention, hypothyroidism and pancreatitis, plus possible QT prolongation as seen with the approved GH stimulator macimorelin. FDA found no data showing it would not [1].

What Thymosin Alpha-1's Own Record Shows

Thymosin alpha-1 is a 28-amino-acid peptide with an acetylated N-terminal end, originally isolated from thymosin fraction 5. Thymalfasin is the synthetic version with the same sequence, and Zadaxin is the brand of finished injection sold outside the US at 1.6 mg per vial [2].

After subcutaneous injection in healthy volunteers it peaks at about 0.7 to 2 hours, clears with a half-life of about 1.8 to 2.6 hours, and did not accumulate over five daily doses [9][2].

It is not FDA-approved. FDA notes four US orphan drug designations, but orphan designation is a separate process and is not an approval [2]. It is authorized as a medicine elsewhere: in Italy, Zadaxin is authorized as an adjuvant to influenza vaccination in immunocompromised people; in India, for chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication; and in Hong Kong [2].

The Italian label gives 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first vaccination, repeated from week 8 to week 12 at the second vaccination. That label says it is not for children, is contraindicated in pregnancy and breastfeeding, calls for caution in people with allergies or autoimmune disease, and calls for caution with other immune-modulating drugs [2].

The hepatitis B evidence is real but weak. A 2026 Cochrane review pooled 10 randomized trials in 1,349 adults published between 1991 and 2018. It found possible lower all-cause mortality (risk ratio 0.53, 95% CI 0.29 to 0.96; 3 trials, 907 people) but rated the certainty very low, found little to no effect on quality of life or liver histology, and the reviewers said they are not sure thymosin alpha-1 helps [5]. One double-blind trial of 98 adults with HBeAg-positive hepatitis B found HBeAg loss at 72 weeks of 45.8% with thymosin alpha-1 plus interferon versus 28.0% with interferon plus placebo, a difference of 17.8% that was not statistically significant (P=0.067) [11].

What Actually Separates Them: Regulatory Status

This is where the two diverge most clearly.

FDA lists ipamorelin acetate in category 2, bulk substances that may present significant safety risks when compounded by outsourcing facilities. It was added September 29, 2023 and is still listed on the page dated 04/22/2026 [4][7]. FDA's stated concerns are possible immunogenicity from aggregation and impurities for certain routes, unnatural amino acids that complicate characterization, and serious adverse events including death when ipamorelin was given intravenously to improve gastric motility [4]. In October 2024, FDA's Pharmacy Compounding Advisory Committee voted 0 yes, 12 no, 1 abstention on ipamorelin free base and the same on ipamorelin acetate, citing a lack of information on safety and efficacy [12].

Thymosin alpha-1 sits differently. It had been in category 2 and moved to the 'nominated but withdrawn' table after the nominators withdrew, but FDA's concerns about immunogenicity for certain routes and inadequate safety information remain posted [4]. It appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians, and it is category 3, 'nominated without adequate support', on the outsourcing-facility list [13][7]. In December 2024 the same advisory committee voted 4 yes and 17 no on both its free base and acetate forms, with members citing no compelling evidence of clinical effectiveness and safety [14].

Neither peptide is among the six named in HHS's October 2026 draft enforcement-discretion policy, and FDA's category 1 policy does not apply to either [15][4][13].

Sports rules also split. WADA names ipamorelin in S2.2.4 (growth hormone secretagogues and mimetics), prohibited at all times in and out of competition, on both the 2026 and 2027 lists [6][16]. Thymosin alpha-1 is not named on either list; WADA does name thymosin-beta-4 and derivatives such as TB-500 in S2.3, which is a different peptide [6][16].

If You Are Weighing One Against the Other

The two have been studied for different things.

For growth hormone, ipamorelin has one published controlled human trial, in postoperative ileus, where it did not separate from placebo on the main endpoint [3]. There is no approved product and FDA found no human data for subcutaneous use [1].

For immune function, thymosin alpha-1 has randomized trials in chronic hepatitis B, though the certainty is very low [5]. It is authorized abroad in Italy as a vaccine adjuvant in immunocompromised people and in India for chronic hepatitis B [2].